Best for Fat Loss

GLP-1 receptor agonists produce clinically significant and consistent fat loss in humans, with robust evidence from multiple large RCTs and meta-analyses demonstrating 2-6 kg fat mass reduction and 12-15% body weight loss depending on dose and agent used.

Tirzepatide is a dual GLP-1/GIP receptor agonist with exceptionally strong evidence for fat loss in adults with obesity. Multiple large, well-designed RCTs and meta-analyses consistently demonstrate clinically meaningful weight reduction of 12-21% over 52-72 weeks, with fat mass comprising ~75% of weight lost.

Creatine monohydrate produces small but consistent reductions in body fat percentage and increases lean body mass when combined with resistance training in humans. Meta-analyses of 100+ studies confirm efficacy, though absolute fat mass loss is minimal in younger adults.

Tesamorelin, a GHRH analog, consistently reduces visceral adipose tissue and trunk fat in humans with HIV-associated lipodystrophy across multiple randomized controlled trials, with effect sizes of 15-24% VAT reduction. Evidence is primarily limited to HIV populations and does not demonstrate significant subcutaneous fat loss or meaningful BMI reduction.

Curcumin supplementation produces modest but consistent reductions in body weight, BMI, and waist circumference in humans, with multiple meta-analyses of RCTs demonstrating statistically significant effects. The evidence is strongest for anthropometric measures and body composition, though absolute effect sizes are small (0.5–2 kg weight loss).

Spirulina supplementation demonstrates consistent, clinically meaningful reductions in body weight, body fat percentage, and BMI across multiple human RCTs and meta-analyses. Effects are modest but proven, particularly when combined with exercise or sustained for ≥12 weeks.

Whey protein supplementation demonstrates consistent, clinically meaningful fat loss benefits when combined with resistance training or caloric restriction in humans. Multiple high-quality RCTs and meta-analyses show significant reductions in fat mass (0.62–1.12 kg) with concurrent preservation or modest gains in lean mass.

Retatrutide is a triple receptor agonist (GLP-1/GIP/glucagon) that demonstrates strong, consistent weight loss efficacy in humans across multiple randomized controlled trials, with mean reductions of 20-24% body weight at highest doses compared to placebo.

Cagrilintide, in combination with semaglutide (CagriSema), demonstrates strong efficacy for fat loss in humans with multiple well-designed RCTs showing 10-13.7% body weight reductions. As monotherapy, cagrilintide alone shows modest but consistent weight loss effects in phase 2 trials.

Dulaglutide is a GLP-1 receptor agonist that produces clinically meaningful weight loss in humans with type 2 diabetes, with multiple large RCTs and meta-analyses demonstrating consistent effects. Evidence quality is strong but dulaglutide ranks below newer agents (semaglutide, tirzepatide) in head-to-head comparisons.

Exenatide produces consistent, clinically meaningful weight loss in humans with type 2 diabetes and obesity, with effect sizes of 1.2-2.9 kg across multiple randomized controlled trials and meta-analyses. Evidence is strong and well-replicated, though exenatide is less effective than newer GLP-1 agonists like semaglutide.

Lixisenatide, a GLP-1 receptor agonist, effectively reduces body weight and improves glycemic control in type 2 diabetes patients. Multiple meta-analyses and comparative RCTs demonstrate consistent weight loss and metabolic benefits, though effect sizes are modest compared to newer agents like semaglutide and tirzepatide.

Pemvidutide, a GLP-1/glucagon dual receptor agonist, demonstrates strong efficacy for fat loss in humans based on limited but high-quality RCT data. A 12-week trial showed dose-dependent weight reductions of 4.3% at the highest dose with statistical significance versus placebo.

Setmelanotide is a melanocortin-4 receptor agonist with proven efficacy for fat loss in specific rare genetic forms of obesity (POMC deficiency, LEPR deficiency, Bardet-Biedl syndrome, and hypothalamic obesity). Multiple human RCTs demonstrate clinically significant weight reductions of 10-51 kg, but efficacy is limited to these genetically defined populations and not for common obesity.

Survodutide, a glucagon/GLP-1 receptor dual agonist, demonstrates strong efficacy for fat loss in humans based on a Phase 2 RCT showing dose-dependent weight reductions of 7-17% over 46 weeks. Evidence is robust but limited to early-stage human trials; Phase 3 cardiovascular outcomes data are pending.

Cinnamon supplementation demonstrates consistent, clinically meaningful reductions in fasting blood glucose, waist circumference, and metabolic syndrome markers across multiple human RCTs. Effect sizes are moderate to large, and results have been independently replicated.

Ashwagandha shows probable efficacy for fat loss primarily through stress-reduction and cortisol-lowering mechanisms, with modest improvements in body weight and composition in humans under chronic stress. However, evidence remains inconsistent—several RCTs show no significant changes in weight or BMI despite improvements in lipid profiles and body composition ratios.

PT-141 (bremelanotide) demonstrates probable efficacy for fat loss in humans through MC4R agonism, with one Phase 1 RCT showing statistically significant reductions in body weight (~1.3 kg) and caloric intake (~400 kcal/day) over 16 days in obese women. However, evidence remains limited to a single small human trial with short duration.

Ibutamoren (MK-677) modestly increases fat-free mass in obese and elderly humans over 8 weeks to 2 years, but evidence for direct fat loss is weak and inconsistent. Studies show improvements in body composition metrics, but total and visceral fat were not significantly reduced in most trials.

ACE-031 shows probable efficacy for increasing lean mass in humans based on multiple RCTs, but evidence specifically for fat loss is limited and inconsistent. Studies demonstrate muscle-building effects, with one trial showing a trend toward reduced fat mass, but this was not a primary outcome and statistical significance was not achieved.

Omega-3 supplementation shows modest, inconsistent effects on fat loss in humans. While some studies report small reductions in waist circumference and body fat percentage, multiple meta-analyses find no significant effect on body weight or BMI, and efficacy varies substantially by population and intervention design.

Magnesium supplementation shows modest, inconsistent effects on fat loss and body composition in humans. While some meta-analyses report small reductions in BMI and waist circumference in specific subgroups (obese individuals, those with insulin resistance), overall effects on weight loss are not statistically significant, and results vary substantially across studies.

Vitamin D3 supplementation shows modest effects on fat loss and body composition in humans, with meta-analyses demonstrating small but statistically significant reductions in BMI and waist circumference, though effects on absolute weight loss are inconsistent and clinically marginal.

Zinc supplementation shows modest but consistent benefits for fat loss and body composition in overweight/obese individuals, with reductions in BMI and triglycerides demonstrated across multiple meta-analyses. However, effects on absolute body weight are small and inconsistent, and efficacy varies significantly by population and dosage.

Berberine shows probable efficacy for fat loss in humans, with multiple RCTs and meta-analyses demonstrating modest but consistent reductions in body weight, BMI, and waist circumference. However, effect sizes are small-to-moderate and study durations are relatively short, preventing a higher confidence tier.

Resveratrol shows modest fat loss effects in humans, primarily on waist circumference and body weight, but effect sizes are small and results are inconsistent across studies. Meta-analyses suggest benefits at doses >400-500 mg/day for durations >12 weeks, though clinical meaningfulness remains unclear.

NMN shows probable efficacy for fat loss in humans based on 2-3 RCTs demonstrating modest weight reduction and improved metabolic markers, but evidence remains limited by small sample sizes, short study durations, and inconsistent effects across physiological outcomes.

Alpha-lipoic acid (ALA) demonstrates modest weight loss benefits in humans, with multiple RCTs showing reductions of 2-5 kg and improvements in BMI, particularly in obese and female populations. However, effects are small, inconsistently replicated across all outcomes, and meta-analyses reveal null findings for many related metabolic parameters.

Collagen peptides show probable efficacy for fat loss when combined with resistance training in humans, with multiple RCTs demonstrating improvements in body composition. However, evidence is limited by modest sample sizes, heterogeneous dosing protocols, and unclear mechanisms specific to fat loss independent of exercise.

Probiotics show probable efficacy for fat loss in humans, with multiple RCTs demonstrating modest reductions in body weight, BMI, and waist circumference, but effects are inconsistent across studies and clinical significance remains modest.

Melatonin shows probable efficacy for modest fat loss in humans, with consistent but small reductions in body weight and anthropometric measures across multiple RCTs. However, effects are inconsistent across different body composition metrics and clinical meaningfulness remains unclear.

Vitamin K2 (MK-7) shows probable benefits for fat loss and body composition, particularly in reducing abdominal and visceral fat in responsive populations, but evidence is limited to small-to-moderate human RCTs with mixed results and has not been independently replicated across diverse populations.

Tongkat Ali shows probable efficacy for fat loss in humans based on one moderate-quality RCT demonstrating BMI reduction, supported by consistent mechanistic findings in animal and cell studies. However, evidence is limited to a single human trial with a blended product, and long-term efficacy remains unproven.

Milk thistle (silymarin) shows probable efficacy for reducing liver fat and improving metabolic markers related to obesity and fatty liver disease in humans, but evidence is limited to small observational studies and one small RCT without consistent body weight loss data.

Black seed oil (Nigella sativa) shows probable efficacy for fat loss in humans with consistent reductions in body weight, BMI, and waist circumference across multiple studies, but evidence is limited by small sample sizes, short intervention periods, and moderate heterogeneity in results.

Elderberry shows probable efficacy for fat loss in animal models through multiple consistent mechanisms, but evidence in humans is limited to one small observational study without proper controls. Animal studies demonstrate meaningful reductions in body weight gain and metabolic improvements, but human proof of efficacy remains inconclusive.

Aged garlic extract shows probable efficacy for fat loss and related metabolic parameters in humans, with consistent results across multiple RCTs demonstrating reductions in body weight, visceral fat, and inflammatory markers. However, effect sizes are modest, sample sizes are small, and the longest human trial lasted only 12 weeks, limiting confidence in long-term efficacy.

Green tea extract (particularly EGCG) shows probable efficacy for fat loss in humans, with multiple RCTs demonstrating modest weight and waist circumference reductions. However, effect sizes are small (typically 1-3 kg over 12 weeks), and evidence remains limited by small sample sizes and inconsistent dosing across studies.

Psyllium husk demonstrates probable efficacy for weight loss in humans with modest effect sizes (−2.1 kg over ~5 months in RCTs), supported by a 2023 meta-analysis and multiple independent human trials. However, evidence is limited by small sample sizes, short durations, and inconsistent secondary outcomes.

Fenugreek demonstrates probable efficacy for fat loss in humans through appetite suppression and selective fat intake reduction, supported by multiple small-to-moderate RCTs and observational studies. However, evidence remains limited by small sample sizes, short treatment durations, and inconsistent effect sizes across studies.

Vitamin C shows a probable but not conclusive association with fat loss, supported by multiple observational studies demonstrating inverse correlations between serum vitamin C and BMI/waist circumference, but with limited high-quality RCT evidence and modest effect sizes.

Iodine supplementation shows probable efficacy for fat loss in iodine-deficient, overweight populations, with one quality RCT demonstrating body fat reduction in males and improved lipid profiles. However, evidence is limited to a small number of human studies with mixed results and population-specific effects.

Fisetin shows promising effects on fat loss and obesity-related markers in both animal and human studies, with one double-blind RCT demonstrating significant weight loss when combined with exercise training. However, efficacy is probable but not conclusive due to limited human trial data and modest sample sizes.

Pycnogenol shows probable efficacy for fat loss and metabolic improvement, demonstrated in multiple human RCTs with consistent reductions in waist circumference and body weight. However, evidence is limited by small sample sizes, short intervention periods, and lack of independent replication.

Beta-glucans show probable efficacy for fat loss in humans, with modest reductions in waist circumference and body weight in overweight/obese populations, but effects are not consistently superior to caloric restriction alone, and human trial evidence remains limited.

Pomegranate extract shows probable efficacy for fat loss in humans through modest improvements in weight, waist circumference, and metabolic markers, but evidence is limited by small sample sizes, short durations, and inconsistent results across studies.

Grape seed extract shows probable efficacy for fat loss in humans, with a 2024 meta-analysis of 30 RCTs (n=1,284) demonstrating significant reductions in body weight and BMI in obese participants. However, effects are modest, most human trials are small (n<100), and the strongest evidence comes from a single meta-analysis rather than independent large-scale RCTs.

Olive leaf extract shows probable efficacy for fat loss when combined with calorie restriction in obese women, demonstrated in 3-4 human RCTs with modest but consistent effects on body weight and fat mass. Efficacy as a standalone intervention without dietary restriction is unproven.

Schisandra chinensis shows probable efficacy for fat loss through multiple mechanisms in humans and animals, supported by 2 human RCTs with modest positive trends and consistent mechanistic evidence across 28 animal studies. However, human evidence remains limited in sample size and duration, and most positive findings come from animal models and in-vitro studies.

CLA demonstrates modest fat loss effects in human RCTs, with meta-analyses showing statistically significant reductions in body fat when combined with exercise. However, effect sizes are small, study durations are relatively short (8-12 weeks), and results in humans are inconsistent, limiting confidence in clinical meaningfulness.

Butyrate supplementation shows probable efficacy for fat loss and metabolic improvement in humans, supported by multiple RCTs and observational studies, but evidence remains limited by small sample sizes, short intervention periods, and inconsistent effect magnitudes across studies.

Forskolin shows modest, inconsistent effects on weight loss and body composition in humans. While a few small RCTs report some benefits (particularly for fat mass preservation and metabolic markers), effect sizes are weak and results have not been independently replicated across studies. Current evidence suggests possible efficacy but is far from conclusive.

Ginkgo biloba extract shows probable efficacy for fat loss through multiple mechanisms (pancreatic lipase inhibition, lipid metabolism regulation, gut microbiota reshaping) supported by 2-3 human RCTs demonstrating modest reductions in BMI, waist circumference, and visceral adiposity index, but evidence is limited by small sample sizes and lack of independent replication.

Panax ginseng shows probable efficacy for fat loss in humans based on limited clinical evidence, with consistent mechanistic support from animal studies. However, evidence remains inconclusive due to very few human RCTs, small sample sizes, and lack of independent replication.

Uridine supplementation shows probable efficacy for fat restoration in HIV lipodystrophy patients, with consistent improvements in limb fat and total body fat across multiple human studies. However, evidence is limited to a specific disease context (antiretroviral-induced lipodystrophy) and results have not been independently replicated in general weight loss or obesity populations.

Glycine supplementation shows promise for improving metabolic markers related to fat loss in humans with obesity, particularly for triglyceride reduction and mitochondrial fuel oxidation. However, evidence remains limited to small human trials without consistent demonstration of actual body weight or fat mass reduction.

5-HTP shows probable efficacy for fat loss in humans based on 5 small-to-moderate RCTs, with consistent effects on fat mass reduction and appetite suppression. However, evidence quality is limited by small sample sizes, short study durations, and lack of independent replication by multiple research groups.

GABA supplementation shows modest benefits for body composition and fat loss in humans when combined with exercise, with 3-4 small RCTs demonstrating improvements in waist circumference, BMI, and fat-free mass. However, evidence remains limited to small sample sizes (n=21-30), and mechanistic studies in animals and tissue culture suggest plausible pathways but do not establish causation in humans.

HMB shows modest benefits for fat loss primarily when combined with resistance training in older adults, but evidence is inconsistent across populations. Multiple meta-analyses report minimal to no significant effects on fat mass reduction in younger adults or athletes.

Taurine supplementation shows probable efficacy for fat loss and metabolic improvement in humans, with multiple small RCTs and meta-analyses demonstrating modest benefits to lipid profiles, insulin sensitivity, and body composition in overweight/obese individuals. However, evidence is limited by small sample sizes, short intervention durations, and inconsistent effects on direct weight loss.

L-carnosine shows probable efficacy for fat loss and metabolic improvements in humans based on one double-blind RCT (n=54) demonstrating significant reductions in fat mass and metabolic markers, supported by consistent animal evidence and mechanistic reviews, but efficacy is not conclusively proven due to limited human trial data.

L-Arginine shows modest evidence for reducing waist circumference (−2.97 cm in meta-analysis) and may improve body composition markers in specific contexts, but does NOT produce significant reductions in body weight or BMI. Effects on fat loss are inconsistent and clinically small across human studies.

Octreotide reduces body weight and fat mass in obese individuals by suppressing insulin secretion, with a meta-analysis showing 3.19 kg weight loss and 5.92 kg fat loss versus placebo. Evidence is moderate: based on a limited number of human RCTs (mostly small, n<30) with consistent directional effects, but results are not independently replicated across large diverse populations.

Peptide YY is an anorexigenic gut hormone that increases with dietary fiber, propionate supplementation, and bariatric surgery, and correlates with reduced food intake and weight loss. However, evidence of direct PYY supplementation or targeted PYY elevation for fat loss in humans is limited to mechanistic observations rather than controlled efficacy trials.

Pramlintide demonstrates modest but clinically meaningful weight loss in humans with diabetes, supported by meta-analysis and observational studies. Efficacy in non-diabetic individuals for fat loss alone remains under-investigated.

NAD+ supplementation shows modest benefits for fat loss and body composition in overweight/obese adults, with one RCT demonstrating 1.9 kg greater weight loss and improvements in cholesterol levels. However, evidence is limited to small human trials with short durations, and most studies show NAD+ improves metabolic parameters without directly targeting fat loss as a primary outcome.

Ginger shows probable efficacy for fat loss in humans based on 3 RCTs, with demonstrated reductions in body weight, body fat percentage, and waist circumference. However, evidence is limited by small sample sizes, short intervention periods, and inconsistent findings on metabolic mechanisms like thermogenesis.

MCT oil produces modest, measurable fat loss and metabolic improvements in humans, supported by a meta-analysis and several small RCTs. Effects are real but clinically small—approximately 0.5 kg more weight loss than long-chain fats over weeks to months.

Apple cider vinegar shows modest benefits for weight loss and BMI reduction in humans based on meta-analyses, with pooled reductions of ~0.39 SMD for body weight and ~0.65 SMD for BMI. However, evidence remains limited to relatively small RCTs and observational studies with heterogeneous designs.

DHEA supplementation shows modest fat loss effects in humans, with meta-analyses demonstrating decreased fat mass and increased lean body mass in elderly populations, but effect sizes are small and clinical significance remains debated.

Caffeine supplementation shows moderate evidence for enhancing fat loss through increased energy expenditure and fat oxidation, particularly when combined with exercise. However, most evidence is acute and short-term; long-term fat loss outcomes are not directly demonstrated in these abstracts.

Ipamorelin may inhibit weight loss in specific disease contexts (cisplatin-induced cachexia in ferrets) and theoretically could improve body composition through GH stimulation, but animal studies show it may actually increase body fat through GH-independent mechanisms. No human efficacy data exists for fat loss.

MOTS-c shows plausible promise for fat loss based on consistent mechanistic pathways and animal studies, but human evidence is limited to observational studies showing inconsistent and sometimes paradoxical associations. No human RCT has demonstrated fat loss efficacy.

SS-31 (elamipretide) shows consistent mechanistic benefits for mitochondrial function in preclinical models and demonstrates modest effects on muscle metabolism and body composition in limited animal studies, but lacks robust human evidence specifically for fat loss. No human RCTs exist demonstrating efficacy for weight loss or fat reduction as a primary outcome.

AOD-9604 shows plausible fat-loss mechanisms in animal models, but no human efficacy data exists. Only one animal study demonstrates actual weight and fat loss effects; clinical development was ongoing as of 2004 but no published human trial results are available in this dataset.

Sermorelin stimulates GH and IGF-1 secretion in humans, but direct evidence for fat loss is absent. All fat loss claims rest on theoretical mechanisms in animal models and mechanistic human studies without body composition endpoints.

LL-37 shows plausible mechanisms for reducing fat accumulation and hepatic steatosis in animal models and demonstrates altered expression in obesity, but human efficacy for fat loss remains unproven. No human RCTs testing LL-37 for weight loss or fat loss outcomes exist.

Kisspeptin is extensively studied as a regulator of the hypothalamic-pituitary-gonadal axis and energy homeostasis, but there is no direct evidence from human trials demonstrating that kisspeptin supplementation or modulation causes fat loss. Current evidence is limited to mechanistic observations in observational studies and animal models.

GHRP-2 increases GH and IGF-1 secretion in humans and stimulates appetite/food intake, but evidence for fat loss efficacy is indirect and limited. No RCT directly measures fat loss as a primary outcome.

GHRP-6 stimulates growth hormone release in humans, but evidence for direct fat loss efficacy is absent. Studies demonstrate GH-stimulating properties and metabolic effects in specific contexts, but no human trials report actual fat loss outcomes or body composition changes as primary endpoints.

Hexarelin stimulates GH release in humans, but evidence for direct fat loss efficacy is limited to animal models and mechanistic studies. No human RCTs demonstrate clinically meaningful weight loss or fat mass reduction.

Melanotan 1 (α-MSH analog) is theoretically relevant to metabolic regulation and energy balance through melanocortin receptor activation, but no direct human evidence for fat loss efficacy exists in these abstracts. Only mechanistic reviews and one human observational study on skin darkening are available.

Melanotan 2 consistently reduces food intake and body/fat mass in animal models through melanocortin receptor activation, but no human efficacy trials exist. Evidence is limited to rodent and non-primate animal studies with no clinical proof of safety or efficacy in humans.

Gonadorelin (GnRH agonist) consistently increases fat mass and body weight in humans across multiple studies, making it contraindicated for fat loss. No evidence demonstrates efficacy for weight loss; rather, the compound promotes weight gain.

Humanin shows metabolic benefits for fat loss in animal models, including reduced weight gain, decreased visceral fat, and improved insulin sensitivity. However, no human clinical trials exist to confirm efficacy in humans.

Follistatin 344 shows promise for fat loss through animal studies and mechanistic human data demonstrating increased follistatin/myostatin ratio, but no direct human evidence that follistatin supplementation itself reduces body fat. All human studies involved exercise or dietary interventions where follistatin changes were a secondary biomarker, not the primary intervention.

GDF11 shows no proven efficacy for fat loss in humans. Animal studies and observational data suggest mixed effects on body composition, but human evidence is absent, inconsistent, or shows potential harm (hepatic fibrosis, muscle wasting in some contexts).

VIP shows plausible mechanisms for fat loss and metabolic regulation based on animal and limited human observational studies, but there is no human RCT evidence demonstrating efficacy for fat loss. Current evidence is insufficient to prove VIP causes clinically meaningful weight loss.

5-Amino-1MQ shows promising fat loss effects in obese mice when combined with dietary intervention, but no human clinical trials have been conducted. Efficacy is plausible based on animal data but remains unproven in humans.

IGF-1 LR3 shows plausible mechanisms for muscle preservation in animal models of cachexia and muscle loss, but all evidence is from rodent studies with inconsistent or limited efficacy results. No human trials exist to demonstrate fat loss benefits.

Oxytocin shows promise for appetite suppression and weight loss in animal models, but human evidence is minimal and inconclusive. A single small human RCT (n=16) found no significant effects on satiety or food intake, though leptin levels decreased. Efficacy in humans remains unproven.

Cortexin has been studied in only 1 small human RCT and 1 observational study for obesity/metabolic outcomes, with no reported quantified efficacy data for fat loss. Evidence is preliminary and insufficient to demonstrate proven efficacy.

NAC shows plausible anti-inflammatory and antioxidant effects relevant to obesity, but human evidence for fat loss is limited to small pilot studies and indirect metabolic markers. No well-designed human RCTs directly demonstrate fat loss or weight reduction as a primary outcome.

Quercetin has been extensively studied for fat loss in humans, but meta-analyses and RCTs consistently show no significant effects on body weight, BMI, or waist circumference. While animal studies suggest potential metabolic benefits through mitochondrial and microbiota mechanisms, these effects do not translate to clinically meaningful weight loss in humans.

CoQ10 shows plausible mechanisms for fat loss through mitochondrial function and white adipose tissue browning, but human evidence for direct weight loss efficacy is limited and inconsistent. Most evidence comes from animal studies or studies examining CoQ10 as part of multi-ingredient formulas.

Rhodiola rosea shows plausible fat-loss mechanisms in animal and in-vitro models, but human evidence is sparse and inconsistent. Only 2 human RCTs exist, neither demonstrating meaningful fat loss as a primary outcome.

Maca root shows potential metabolic effects in animal models, particularly on insulin signaling and fat tissue regulation, but there is zero human evidence specifically for fat loss. All efficacy data come from rodent studies.

Glucosamine + chondroitin has not been shown to promote fat loss in humans. Evidence is focused on osteoarthritis symptom management, with no clinical trials demonstrating weight loss efficacy for this supplement combination.

Vitamin B12 has been studied in humans primarily for metabolic outcomes in specific populations (bariatric surgery, type 2 diabetes), with one RCT showing modest BMI reduction when combined with diabetes medication. However, direct evidence for B12 as a standalone fat loss intervention in humans is minimal and indirect.

Vitamin E shows no significant effect on direct fat loss outcomes (weight, BMI, waist circumference) in humans, though it may modulate inflammation and lipid metabolism relevant to obesity. Evidence remains largely mechanistic or observational rather than demonstrating proven efficacy for weight reduction.

Iron supplementation shows plausible effects on fat loss through leptin regulation and metabolic efficiency in humans, but evidence is limited to a small number of mechanistic studies and short-duration trials without consistent, clinically meaningful fat loss outcomes.

Selenium supplementation shows plausible mechanisms for fat loss through effects on thyroid function, adipose tissue metabolism, and oxidative stress, but human evidence for direct fat loss remains weak and inconsistent. Most positive findings come from small RCTs or animal models; large-scale human trials show mixed or null results.

Chromium supplementation shows minimal to no proven efficacy for fat loss in humans. Multiple meta-analyses and RCTs demonstrate statistically significant but clinically negligible weight reductions (~1 kg), with results heavily dependent on single outlier studies and inconsistent across populations.

Biotin's effects on fat loss are supported only by animal studies showing modest improvements in lipid metabolism and adipose tissue markers, with no human RCTs demonstrating efficacy for weight loss or fat reduction.

Spermidine shows consistent weight loss and metabolic benefits in multiple animal models of diet-induced obesity, but evidence is limited to only 2 human RCTs (one ongoing/protocol only, one small observational study). Efficacy is plausible but not yet proven in humans.

Urolithin A shows plausible mechanisms for fat loss in preclinical studies and observational human data, but direct evidence of efficacy for weight loss in humans is absent. Available human evidence is correlational or indirect, not from controlled trials specifically testing fat loss outcomes.

Astaxanthin shows modest effects on fat oxidation and body composition in animal models and limited human studies, but meta-analyses of human RCTs found no significant effects on BMI, body weight, or fat loss. Efficacy in humans for fat loss is not proven.

One small human RCT (n=20) demonstrated that glutathione supplementation improves insulin sensitivity in obese subjects, which is metabolically relevant to fat loss but does not directly prove fat loss efficacy. Animal studies show mechanistic support but no direct evidence of body composition changes.

One human RCT shows DIM produced a statistically significant reduction in body fat percentage versus placebo in premenopausal women, but the study was small (n=60), short-term (30 days), and the primary mechanism of action (estrogen metabolism) was not achieved at the tested dose. Efficacy for fat loss is plausible but not yet proven.

Boswellia serrata shows plausible anti-obesity mechanisms in animal models and in vitro studies, but evidence of efficacy for fat loss in humans is absent. No human RCTs specifically testing weight loss or body composition endpoints exist.

TUDCA shows consistent effects on metabolic markers and weight reduction in animal models, but human evidence for fat loss is extremely limited. Only one small human RCT exists, showing improved insulin sensitivity but no direct measurement of fat loss or body weight change.

Nattokinase has not been proven effective for fat loss in humans. One human RCT showed improved insulin resistance markers in a multi-ingredient formula, and animal studies suggest potential lipid-lowering effects, but direct evidence of fat loss in humans is absent.

Shilajit shows plausible mechanisms for metabolic support in humans, but lacks direct evidence of fat loss efficacy. Three human RCTs exist, but none measured fat loss or weight change as primary outcomes; instead they focused on gene expression, skin perfusion, and metabolic markers in the context of combined interventions.

Bovine colostrum supplementation has been studied in 10 human RCTs, but none demonstrate efficacy for fat loss. Studies consistently show no significant changes in body composition, body weight, or fat mass compared to control proteins.

Cordyceps militaris shows anti-obesity effects in animal models through multiple mechanisms, but zero human clinical trials exist to prove efficacy in humans. All evidence comes from rodent studies and in-vitro work.

Reishi (Ganoderma lucidum) polysaccharides show consistent anti-obesity effects in animal models through gut microbiota modulation and enhanced lipolysis, but no human randomized controlled trials exist to prove efficacy in humans. All evidence of fat loss comes from rodent studies or mechanistic reviews.

Chaga shows promise for fat loss in animal models through multiple mechanisms involving gut microbiota modulation, energy metabolism, and lipid regulation, but human efficacy remains completely unproven. The single human RCT identified was actually a study on colitis, not fat loss.

Epicatechin shows promise for fat loss and metabolic health through animal studies and mechanistic research, but human efficacy remains largely unproven. Only one large human RCT exists, which showed null results for diabetes prevention.

Pterostilbene shows consistent anti-obesity and fat-loss mechanisms in animal models and cell cultures, with promising effects on body composition and metabolic markers. However, human evidence is limited to 3 small RCTs with mixed results, and the largest human trial (n=80) actually reported increased LDL with pterostilbene monotherapy, limiting confident claims of efficacy for fat loss in humans.

MSM has not been proven effective for fat loss in humans. A single small RCT (n=22) showed improved HDL cholesterol but no significant effects on body composition, weight, or metabolic rate—the primary outcomes relevant to fat loss.

Bromelain shows plausible mechanisms for supporting fat loss through anti-inflammatory and metabolic effects in animal models, but human efficacy for fat loss remains unproven. No human RCTs demonstrating weight loss or fat reduction exist in this literature.

Stinging nettle shows consistent beneficial effects on fat loss and metabolic parameters in rodent models, with emerging evidence from a small human observational study on PCOS. However, efficacy in humans remains unproven due to lack of dedicated human RCTs specifically testing fat loss as a primary outcome.

Mucuna pruriens shows promising anti-obesity effects in rodent models with reductions in body weight, fat mass, and metabolic markers, but human evidence for fat loss is absent. The only human RCTs tested pre-workout formulations containing Mucuna as one ingredient among many, with no isolated fat loss outcomes reported.

Ecdysterone shows consistent fat-loss effects in animal models and one small human RCT, with clear mechanistic support for lipolysis and fat oxidation. However, efficacy in humans remains largely unproven due to extremely limited human data (only 1 small RCT, n=20).

Cistanche shows promise for fat loss and metabolic improvement in animal models, with one human RCT demonstrating fatigue reduction (not directly fat loss). Human efficacy for weight loss remains unproven.

Tribulus terrestris shows no proven efficacy for fat loss in humans. Four human RCTs consistently demonstrate null or minimal effects on body composition, while animal studies suggest potential mechanisms via anti-inflammatory and metabolic pathways that have not translated to meaningful human weight loss outcomes.

Valerian root shows anti-obesity potential in animal and cell culture studies, but no human clinical trials have tested its efficacy for fat loss. Current evidence is limited to mechanistic research in mice and adipocyte models.

Lemon balm extract shows consistent anti-obesity and metabolic effects in animal models (primarily rodents), with evidence suggesting mechanisms via angiogenesis inhibition and PPAR activation. However, no human clinical trials exist to demonstrate efficacy in humans, limiting conclusive proof of effectiveness for fat loss.

Pregnenolone levels correlate with body composition and obesity markers in observational studies, but there is no direct evidence that pregnenolone supplementation causes fat loss in humans. Evidence is limited to associations between circulating pregnenolone and adiposity, with no RCTs demonstrating efficacy for weight loss.

Rapamycin shows fat loss effects in animal models and one small human RCT, but human evidence is limited and contradicted by metabolic side effects. In humans, efficacy is plausible but not yet proven.

Astragalus shows plausible anti-obesity mechanisms in animal models and limited human data, but lacks sufficient human clinical evidence to prove efficacy for fat loss. One small human RCT and mixed observational data suggest potential, but results are not conclusive.

Betaine supplementation shows mixed and contradictory effects on fat loss in humans. While some small RCTs and one meta-analysis reported modest reductions in body fat, a more recent and comprehensive meta-analysis found no significant effects on body composition, and multiple individual RCTs showed null results.

Lion's Mane shows plausible anti-obesity mechanisms in animal models and one small human observational study, but lacks rigorous human RCT evidence. Efficacy for fat loss in humans remains unproven.

Huperzine A has not been studied for direct fat loss in humans. Animal studies show it may improve cognitive function in obese mice without affecting body weight or peripheral metabolism, but there is no evidence of efficacy for the fat loss goal itself.

PQQ shows plausible fat-loss potential through mitochondrial biogenesis and metabolic improvements in animal models, but human efficacy for fat loss remains unproven. Two small human studies exist but neither directly measured fat loss outcomes.

Piracetam and its derivative S-phenylpiracetam show modest effects on body weight in animal models, but human evidence for fat loss efficacy is extremely limited and inconsistent. One observational study found piracetam use associated with increased dementia risk, raising safety concerns.

S-phenylpiracetam reduced body weight gain and fat mass in rodent models (obese rats and high-fat diet mice) without increasing activity levels, but no human RCTs exist for phenylpiracetam and fat loss. Evidence is limited to a single animal study.

Vinpocetine shows consistent anti-obesity effects in animal models through PDE1 inhibition and enhanced lipolysis, but human efficacy for fat loss remains unproven—only one observational study mentions weight loss as part of a multi-intervention protocol with no isolated vinpocetine effect data.

Centrophenoxine has not been proven effective for fat loss in humans. The limited human evidence shows increased intracellular water content but no direct fat loss outcomes; animal studies suggest potential anti-aging effects on cellular membranes but are not relevant to weight loss goals.

L-theanine shows plausible mechanisms for fat loss support (AMPK activation, adipose tissue browning, lipid oxidation) based on mechanistic reviews and animal studies, but no human RCTs or observational studies on fat loss outcomes exist in this dataset. Efficacy in humans remains unproven.

L-glutamine supplementation shows plausible effects on gut microbiota composition and obesity-related biomarkers in humans, but evidence of direct fat loss efficacy is weak, limited to small pilot studies, and lacks replication by independent groups.

Acetyl-L-Carnitine shows plausible mechanisms for fat loss and metabolic support, but human evidence for direct fat loss efficacy is sparse and mixed. Most positive findings come from small studies combining it with other compounds or in disease-specific populations (PCOS, HIV lipoatrophy), not in general weight loss.

Beta-alanine has no proven efficacy for fat loss in humans. Multiple meta-analyses of RCTs show no significant effects on fat mass, body fat percentage, or body composition despite theoretical mechanisms.

L-Citrulline shows no consistent benefit for fat loss as a standalone intervention. Meta-analyses and RCTs demonstrate minimal to no effects on body weight, BMI, or fat mass in general populations, though subgroup findings suggest potential effects at higher doses (>6 g/day) or in older adults (>40 years) warrant further investigation.

BCAAs for fat loss lack proven efficacy in humans. While mechanistic studies and animal models suggest potential for muscle preservation during weight loss, human RCT evidence is limited, inconsistent, and fails to demonstrate meaningful fat loss benefits. High circulating BCAA levels are actually associated with increased obesity and type 2 diabetes risk.

Leucine supplementation shows promise for preserving lean mass during caloric restriction and resistance training in humans, but evidence of actual fat loss efficacy is limited and inconsistent. Most positive findings come from small human trials or animal models, with several human RCTs showing null or mixed results.

L-serine has been studied primarily in animal models and niche neurological conditions (hereditary sensory neuropathy), with only one small human observational study showing relevance to fat loss via intestinal development in broilers. No human RCT evidence demonstrates efficacy for fat loss in humans.

Adipotide shows weight loss and metabolic improvements in primate studies through targeted destruction of fat tissue blood vessels, but efficacy in humans remains unproven. Only one non-human primate observational study exists; no human RCTs have been conducted.

Ghrelin is a natural hunger hormone that increases during weight loss, which paradoxically makes maintaining fat loss harder—but modulating ghrelin itself has not been proven effective for fat loss in humans. Studies show ghrelin dynamics during weight loss but not that lowering ghrelin causes fat loss.

Linaclotide shows potential for weight loss through activation of brown adipose tissue and gut-brain signaling in animal studies and mechanistic research, but lacks rigorous human RCT evidence. One real-world observational study associated linaclotide use with modest weight loss in semaglutide patients, but this was not the primary outcome and causality cannot be established.

Nesfatin-1 is an anorexigenic peptide studied for fat loss potential, but human evidence is limited to observational studies showing lower nesfatin-1 levels in obese individuals — not proof that administering nesfatin-1 causes weight loss. No human RCTs demonstrate efficacy for fat loss.

Neuropeptide Y (NPY) is a well-characterized orexigenic (hunger-promoting) peptide involved in energy homeostasis, but evidence for its use as a fat-loss intervention in humans is extremely limited. Available evidence consists primarily of mechanistic studies and animal models showing that blocking NPY signaling (via receptor antagonists) may reduce appetite and promote weight loss; human efficacy data are minimal.

Orexin-A is involved in regulating food intake and energy expenditure based on animal and limited human studies, but there is no clinical evidence that supplementing or increasing orexin-A actually causes fat loss in humans.

PACAP shows promise for fat loss through multiple mechanistic pathways in animal studies and theoretical frameworks, but no human RCT evidence demonstrates that PACAP supplementation actually reduces body fat or weight in people. Current evidence is preclinical and mechanistic only.

Teriparatide shows promise for reducing fat accumulation in bone marrow and preventing muscle/fat changes in specific injury contexts, but evidence for direct fat loss as a primary goal is minimal and indirect. No human RCTs demonstrate teriparatide as an effective fat loss agent.

Calcium supplementation shows no consistent benefit for fat loss in most populations. While some studies suggest small effects in specific subgroups (children, adolescents, premenopausal women), the largest and most rigorous trials in overweight and obese adults found no meaningful weight or fat reduction.

Manganese supplementation shows consistent effects on lipid metabolism markers in animal studies, reducing hepatic lipid content and altering fat-related enzyme activity. However, no human RCTs directly measuring fat loss, body weight reduction, or body composition changes exist—all evidence comes from poultry and rodent models.

Vitamin B3 (as nicotinamide and nicotinamide riboside) shows promise for metabolic health and body composition in preliminary human studies, but direct evidence for fat loss remains limited and mixed. One human RCT demonstrated increased fat-free mass and metabolic rate, but no clear reduction in body fat percentage.

Folate supplementation does not reliably improve fat loss or body weight in the general population. However, limited evidence suggests potential metabolic benefits in specific subgroups (elevated homocysteine, PCOS) and improvements in insulin resistance markers in overweight/obese individuals.

Luteolin shows promise for fat loss through anti-inflammatory and metabolic effects in animal and in-vitro studies, but no human randomized controlled trials have demonstrated efficacy for weight loss or fat reduction.

Lecithin shows promise for reducing abdominal fat and improving lipid metabolism in animal models, but human evidence is absent. Current data is insufficient to conclude that lecithin effectively promotes fat loss in people.

Vitamin K1 has not been proven to directly improve fat loss in humans. While observational studies suggest associations between higher vitamin K1 intake and better metabolic markers (insulin sensitivity, body composition), no randomized controlled trials demonstrate that vitamin K1 supplementation causes weight loss or fat reduction.

Lutein supplementation shows some promise for improving lipid profiles and reducing inflammatory markers in adults with central obesity, but human evidence is limited to 3 small RCTs with modest, inconsistent effects on actual fat loss and body composition. Most research focuses on eye and brain health, not weight loss.

Beetroot juice (dietary nitrate) shows promise for improving exercise performance in specific populations, but evidence for fat loss specifically is absent. The studies demonstrate ergogenic effects on muscle power and exercise tolerance, not weight loss or body composition changes.

One human RCT shows burdock root extract may modestly improve certain metabolic markers in elderly women with metabolic syndrome, but efficacy for fat loss specifically is not clearly demonstrated and results were not superior to exercise alone.

Kelp shows modest fat loss benefits in one human RCT (males only), but evidence is limited by small sample size, sex-specific results, and serious safety concerns regarding thyroid dysfunction from excessive iodine content that overshadow any weight loss benefit.

Chlorophyll supplementation prevented diet-induced obesity and improved metabolic markers in young mice, but no human studies exist. Efficacy in humans remains unproven.

Black pepper (piperine) shows promise for fat loss in animal models when combined with curcumin under caloric restriction, but no human trials have demonstrated efficacy. Evidence is limited to one animal study and one review discussing safety concerns.

Moringa shows promising anti-obesity and lipid-lowering effects in animal models, but direct evidence of fat loss efficacy in humans is minimal. The single human study found lycopene superior to moringa for metabolic outcomes.

No evidence supports BPC-157 for fat loss. Studies focus on wound healing and gastrointestinal conditions, with only incidental weight loss observations in disease models.

TB-500 has not been directly studied for fat loss in humans. The available evidence consists primarily of animal studies and reviews examining its effects on fat grafting survival and adipose tissue function, not fat loss.

GHK-Cu has not been studied for fat loss in humans or animals. The available evidence addresses muscle dysfunction in COPD and colitis inflammation, with no data on adiposity, weight loss, or metabolic effects relevant to fat loss.

No human evidence exists for CJC-1295's efficacy in fat loss. Available data consists of one netnographic review of online forum discussions (no clinical outcomes measured) and one animal study in knockout mice showing normal body composition but not fat loss specifically.

No evidence that Semax promotes fat loss in humans. The single available study investigated spinal cord injury recovery in female mice with no measurement of body composition or weight loss.

Selank has not been studied for fat loss in any human or animal model. The single available study examined selank's effects on neurological recovery after experimental hemorrhagic stroke in rats, with no measurement of body composition or weight loss efficacy.

No human or animal efficacy studies exist for DSIP and fat loss. The only available evidence is a theoretical review suggesting DSIP (via GILZ regulation) *could* influence circadian control of adipose tissue metabolism, but this remains mechanistic speculation without any demonstrated clinical or experimental proof of efficacy.

KPV has been studied only in animal models for inflammatory bowel disease, not for fat loss. There is no evidence that KPV promotes fat loss in any organism.

No human evidence supports thymalin for fat loss. The only animal study examined thymic function and weight maintenance post-thyroidectomy, not fat loss specifically, and did not quantify body composition changes or metabolic effects relevant to weight management.

MGF has not been studied for fat loss in humans. All evidence is mechanistic or shows MGF's role in muscle growth/maintenance through animal and in-vitro studies, but no direct evidence demonstrates MGF reduces body fat or improves fat loss outcomes in any human trial.

Boron has not been demonstrated to improve fat loss in humans. The two human RCTs available show no effect on relevant body composition or metabolic outcomes, while animal studies focus on bone health and reproductive toxicity rather than fat loss mechanisms.

Saw palmetto has not been demonstrated to promote fat loss in humans. The single human RCT mentioning it was part of a multi-ingredient formula where saw palmetto's individual contribution cannot be isolated, and no studies directly evaluated saw palmetto monotherapy for fat loss or body composition changes.

Vitamin B Complex has not been demonstrated to cause fat loss in humans. While B vitamins play roles in metabolism and are frequently deficient in obesity, no human RCTs or observational studies in the provided abstracts show that B vitamin supplementation produces meaningful weight loss or fat reduction.

Copper supplementation has not been demonstrated to promote fat loss in humans. Evidence consists primarily of animal studies in livestock and poultry showing mixed effects on body composition, plus observational case reports of copper deficiency in bariatric surgery patients—a context irrelevant to intentional weight loss supplementation.

Turkey Tail has no demonstrated efficacy for fat loss. The single available study is a toxicology assessment in rats that does not evaluate weight loss, body composition, or metabolic outcomes.

Apigenin has no demonstrated efficacy for fat loss. The single available study on PubMed examined apigenin's association with sleep quality in humans, not body composition or weight loss.

No human evidence supports lactoferrin for fat loss. The three available studies examine growth in preterm infants, fish intestinal health, and bone metabolism in ovariectomized mice—none directly measure or report fat loss outcomes.

Turkesterone reduced lipid accumulation in human adipocyte cell cultures, but this is in-vitro evidence only with no human trials, animal studies, or clinical efficacy data for fat loss.

Echinacea has not been studied for fat loss in humans. The single human RCT identified was a broiler chicken study mislabeled as human, and remaining evidence consists of animal studies examining immune function and weight changes in disease models, none of which demonstrate efficacy for fat loss as a primary outcome.

Kava is not supported by evidence for fat loss. While one review mentions weight loss as a causality-indicated effect of chronic kava consumption, this finding is isolated and not replicated in the available literature. No studies specifically investigated kava for weight loss efficacy.

Passionflower has NOT been studied for fat loss in humans. All available evidence focuses on sleep, anxiety, and neurological effects in rodent models or reviews. There is zero direct evidence that passionflower promotes weight loss or fat loss.

Methylene blue has not been studied for fat loss in humans. The five available abstracts on methylene blue address sepsis, ifosfamide encephalopathy, exercise-induced neurological damage, and use as a tracer dye in gastrointestinal studies—none directly evaluate fat loss or weight reduction efficacy.

Lithium orotate has not been studied for fat loss in humans or animals. The only available evidence consists of one observational study on alcoholism treatment (with concurrent dietary intervention) and one animal study on GSK3β inhibition in an obesity model—neither directly measures or demonstrates fat loss efficacy.

SAMe is not studied for fat loss in humans. All relevant evidence is mechanistic, describing SAMe's role in metabolic pathways and methylation reactions, with no direct efficacy data for weight reduction or fat loss in any human trials.

Hyaluronic acid has not been proven effective for fat loss. The single human RCT studied it for knee osteoarthritis pain in overweight patients and showed improvements in pain/function and inflammatory markers, but did not measure or report any fat loss outcomes. The second study is an in-vitro bovine oocyte maturation study completely unrelated to fat loss in humans.

Peppermint oil has not been studied as a direct intervention for fat loss in humans. The available evidence only mentions peppermint oil incidentally as a potential IBS symptom reliever, with no efficacy data for weight loss or fat loss.

Alpha-GPC has not been demonstrated to promote fat loss. The single human RCT examined cardiovascular recovery post-exercise in overweight women, not weight loss or body composition outcomes. The review article merely notes α-GPC's presence in mushroom mycelia without discussing efficacy for any health goal.

Bacopa monnieri has not been studied for fat loss in humans. The single human trial examined ADHD symptoms, not weight management. Animal studies show potential metabolic effects (increased liver glycogen, improved glucose utilization), but no direct evidence of fat loss in any study.

Phosphatidylserine (PS) has been studied only as a biomarker of cellular dysfunction in obesity, not as a therapeutic intervention for fat loss. No evidence demonstrates that PS supplementation promotes weight loss or improves body composition in humans.

CDP-choline has not been studied for fat loss in humans. All evidence is mechanistic (animal/cell studies on phospholipid metabolism and liver lipid handling) with no demonstrated efficacy for weight reduction or body composition in any human trial.

Noopept has not been studied for fat loss in humans. A single animal study found it improved metabolic markers in diabetic rats, but this does not constitute evidence of efficacy for fat loss as a health goal.

Aniracetam has no demonstrated efficacy for fat loss. The only relevant study found that aniracetam had no effects on food intake, fluid intake, or body weight in rats of any age.

Bromantane has not been studied for fat loss efficacy in humans or animals. The only available evidence consists of two rat studies examining reproductive and developmental outcomes, neither of which measured or reported fat loss, body composition, or weight loss as primary endpoints.

There is no evidence that DMAE is effective for fat loss. The two available abstracts on PubMed do not contain any studies investigating DMAE for weight loss or body composition outcomes.

L-Tyrosine has not been demonstrated to produce meaningful fat loss effects in humans. The available evidence consists primarily of mechanistic reviews and studies of multi-ingredient supplements where L-Tyrosine's independent contribution to fat loss cannot be isolated.

D-aspartic acid has no proven efficacy for fat loss. The only human RCTs examining D-aspartic acid for body composition found no effect on fat mass, body weight, or fat-free mass compared to placebo.

Tryptophan has not been demonstrated to directly promote fat loss in humans. While tryptophan influences serotonin metabolism and appetite regulation pathways, the available evidence shows only mechanistic associations and observational correlations with obesity, without any human RCT proving efficacy for weight loss or fat reduction.

Larazotide has no demonstrated efficacy for fat loss. The available evidence describes its mechanism for celiac disease (tight junction regulation) and shows safety in an animal colitis model, but no studies examine or demonstrate weight loss or fat loss effects in any population.

Abaloparatide has not been studied for fat loss. The available evidence discusses its use for osteoporosis treatment and bone health, with no abstracts reporting effects on body weight, adiposity, or fat reduction.

Cortistatin has not been studied for fat loss in humans. Animal studies suggest it may influence metabolic parameters through effects on the GH/IGF-I axis and ghrelin system, but no direct evidence of fat loss efficacy exists in any species.

IGF-1 DES has not been proven effective for fat loss in humans. The available evidence consists of one observational study in gastric bypass patients (where weight loss was induced by surgery, not the compound) and one animal study focused on diabetic retinopathy, neither of which demonstrates efficacy for fat loss as a primary outcome.

Lanreotide is not established as an effective treatment for fat loss. No studies in these abstracts demonstrate that lanreotide produces meaningful weight loss or fat mass reduction as a primary therapeutic goal.

Matrixyl (Pal-KTTKS) has not been studied for fat loss in humans or animals. The only available PubMed abstract describes its use in wound healing via collagen synthesis stimulation in a rat burn model, which is entirely unrelated to fat loss.

Thymopentin has not been studied for fat loss in humans. The 13 abstracts discuss its immunomodulatory effects in infection, HIV, and colitis — not weight management or body composition. One animal study mentions weight loss as a secondary outcome in cancer cachexia, but this reflects disease-related wasting, not intentional fat loss.

Thymulin has not been studied for fat loss in any human trials. The only human study examining thymulin during caloric restriction found no change in thymulin activity, providing no evidence that thymulin affects weight loss.

Vosoritide is mentioned as an investigational drug for achondroplasia complications, but the available abstracts provide no evidence of efficacy for fat loss. The only mentions occur in reviews discussing FGFR3 signaling modulation in a genetic condition unrelated to weight management.

The provided abstracts do not contain any studies specifically investigating 'C-10' as a compound for fat loss. The abstracts appear to be mismatched to the research question and do not provide evidence of efficacy for this goal.

CAAKG has not been studied for fat loss in humans. The abstracts provided discuss the FTO gene — a genetic locus associated with obesity risk — but do not evaluate CAAKG supplementation as a fat loss intervention.

Vitamin B1 supplementation has no proven efficacy for fat loss. The limited human evidence shows B1 does not improve weight loss outcomes, and research focuses primarily on preventing thiamine deficiency-related neurological complications in bariatric surgery patients, not on achieving fat loss.

No evidence demonstrates that vitamin B2 improves fat loss in humans. The available research consists of one small human RCT unrelated to fat loss, one observational study on micronutrient status in elderly adults with no fat loss outcomes, and three review/animal studies that do not establish human efficacy for weight loss.

No evidence demonstrates that vitamin B6 improves fat loss in humans. The abstracts contain no human studies testing B6 for weight loss, and animal studies focus on metabolic markers rather than actual fat loss outcomes.

Lycopene has not been demonstrated to improve fat loss in humans. Studies show it may modulate inflammatory markers and adipokines in obese rodents, but no human RCTs confirm weight loss or fat reduction efficacy.

Zeaxanthin has not been studied for fat loss in humans. All evidence relates to eye health and cognitive function, not weight management or body composition.

The single available study examined drug-supplement interactions in rats, not fat loss efficacy. No human evidence demonstrates that bladderwrack extract actually promotes weight loss.

Sea moss extract has not been studied for fat loss in humans. One review mentions seaweed extracts may inhibit adipocyte differentiation in cell culture, but no human trials exist demonstrating efficacy for weight loss or fat reduction.

No evidence supports dandelion for fat loss. The only study examined colitis and gut inflammation in mice, not weight loss or fat metabolism in any organism.

Yellow Dock (Rumex acetosa) shows in-vitro enzyme inhibition activity and one animal study demonstrating improved glucose control in diabetic mice, but there is no human evidence of efficacy for fat loss.

No human evidence exists that manuka honey improves fat loss. The available studies examine only antibacterial mechanisms in test tubes and do not assess weight loss, body composition, or metabolic outcomes relevant to fat loss.

The abstracted research does not demonstrate that vitamin A supplementation effectively promotes fat loss in humans. Studies show vitamin A's role in metabolism and fat tissue development, but no human trials report fat loss as an outcome.

One 1968 rat study found that excess molybdenum caused weight loss, but this was a side effect of toxicity, not an intentional fat loss mechanism. No evidence supports molybdenum supplementation as an effective fat loss agent in humans or animals.

Slippery elm has not been shown to improve fat loss or body composition in humans. The only rigorous study (RCT) found no beneficial effects on body composition, waist circumference, or other measured outcomes.